Standout Papers

The PREMIER study: A multicenter, randomized, double‐blind clinical ... 1997 2026 2006 2016 1.4k
  1. The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment (2005)
    Ferdinand C. Breedveld, Michael H. Weisman et al. Arthritis & Rheumatism
  2. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein (1997)
    Larry W. Moreland, Scott W. Baumgartner et al. New England Journal of Medicine
  3. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks (2006)
    Stanley Cohen, Paul Emery et al. Arthritis & Rheumatism
  4. Denosumab in Postmenopausal Women with Low Bone Mineral Density (2006)
    Michael R. McClung, E. Michael Lewiecki et al. New England Journal of Medicine
  5. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis (2012)
    Ronald van Vollenhoven, Roy Fleischmann et al. New England Journal of Medicine
  6. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression (2004)
    Philip J. Mease, Alan Kivitz et al. Arthritis & Rheumatism
  7. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study (2013)
    Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism
  8. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials (2017)
    Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases
  9. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study (2019)
    Josef S Smolen, Aileen L. Pangan et al. The Lancet
  10. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme (2020)
    Stanley Cohen, Ronald van Vollenhoven et al. Annals of the Rheumatic Diseases
  11. Oral surveillance and JAK inhibitor safety: the theory of relativity (2022)
    Kevin Winthrop, Stanley Cohen Nature Reviews Rheumatology
  12. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis (2023)
    Gerd R Burmester, Stanley Cohen et al. RMD Open

Immediate Impact

2 by Nobel laureates 5 from Science/Nature 155 standout
Sub-graph 1 of 13

Citing Papers

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
2023 Standout
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
2021 Standout
8 intermediate papers

Works of Stanley Cohen being referenced

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
2019 Standout
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
2012 Standout
and 10 more

Author Peers

Author Last Decade Papers Cites
Stanley Cohen 10300 4421 4591 212 17.9k
Ben A. C. Dijkmans 17930 6125 6033 330 24.4k
Harvinder S. Luthra 13513 4780 3534 94 20.0k
Ferdinand C. Breedveld 14895 5318 5300 179 21.4k
Alan Kivitz 7180 4379 3209 264 12.4k
Daniel E. Fürst 12018 4535 5160 252 21.5k
Mark C. Genovese 13775 8351 6345 315 22.2k
Bernard Combe 9754 3210 3633 475 13.9k
Roy Fleischmann 16321 6243 8026 346 22.3k
Edward Keystone 16716 6675 7726 400 24.0k
Douglas J. Veale 6204 4198 2161 284 12.7k

All Works

Loading papers...

Rankless by CCL
2026